@TumorBoardTues 1/19 #TumorBoardTuesday #BreastCancer #OncTwitter @maryam_lustberg
36yo π©π»β𦱠self palpates a R breast mass.
PMH: Crohnβs disease - dx 34yo, perianal fistula w/abscess, achieving remission with infliximab/AZA.
π§ͺWorkup: T2N1 TNBC germline neg
π€¨What option would you consider?
36yo π©π»β𦱠self palpates a R breast mass.
PMH: Crohnβs disease - dx 34yo, perianal fistula w/abscess, achieving remission with infliximab/AZA.
π§ͺWorkup: T2N1 TNBC germline neg
π€¨What option would you consider?
@TumorBoardTues @maryam_lustberg 2/19 #TumorBoardTuesday #IBD #BCSM
π©π»βπ¦±patient concerns:
Whatβs SOC for my BC?
Can we minimize IO use?
Were autoimmune dz pts studied?
Will #IBD flare on IO?
Will IO have efficacy while on immunosuppression?
How to decide next steps?
π©π»βπ¦±patient &π©π»ββοΈdoctors β‘οΈβ‘οΈ
LETβS REVIEW DATAβΌοΈ
π©π»βπ¦±patient concerns:
Whatβs SOC for my BC?
Can we minimize IO use?
Were autoimmune dz pts studied?
Will #IBD flare on IO?
Will IO have efficacy while on immunosuppression?
How to decide next steps?
π©π»βπ¦±patient &π©π»ββοΈdoctors β‘οΈβ‘οΈ
LETβS REVIEW DATAβΌοΈ
@TumorBoardTues @maryam_lustberg @WLybaert @shimoi_oncology @AnisToumeh @MamMa_mimumemo @benjiwal @mariani_m97 @SheydaDoc @FelipeBatalini @Dr_RShatsky @DanielleZakon @Badr_AlBawardy @fedgiugliano @DraAnaCasas @LCalabreseDO @DVinsard @drjeffreygraham @Hanna_Huebner @hoperugo @FilippoMontemu1 @PGrivasMDPhD
@TumorBoardTues @maryam_lustberg @WLybaert @shimoi_oncology @AnisToumeh @MamMa_mimumemo @benjiwal @mariani_m97 @SheydaDoc @FelipeBatalini @Dr_RShatsky @DanielleZakon @Badr_AlBawardy @fedgiugliano @DraAnaCasas @LCalabreseDO @DVinsard @DrJeffreyGraham @Hanna_Huebner @hoperugo @FilippoMontemu1 @PGrivasMDPhD 3/19 #TumorBoardTuesday #BreastCancer @MPishvaian @JohnEbbenMDPhD @stolaney1 @TNBCFoundation @LoiSher
π©π»βπ«Mini-Tweetorial 1 π©π»βπ«
π Whatβs the SOC for stage II germline-negative TNBC?
β¨KEYNOTE-522: neoadj pembro + chemo > adj pembro
π#PeterSchmid @BCJoyceO nejm.org
π©π»βπ«Mini-Tweetorial 1 π©π»βπ«
π Whatβs the SOC for stage II germline-negative TNBC?
β¨KEYNOTE-522: neoadj pembro + chemo > adj pembro
π#PeterSchmid @BCJoyceO nejm.org
@TumorBoardTues @maryam_lustberg @WLybaert @shimoi_oncology @AnisToumeh @MamMa_mimumemo @benjiwal @mariani_m97 @SheydaDoc @FelipeBatalini @Dr_RShatsky @DanielleZakon @Badr_AlBawardy @fedgiugliano @DraAnaCasas @LCalabreseDO @DVinsard @DrJeffreyGraham @Hanna_Huebner @hoperugo @FilippoMontemu1 @PGrivasMDPhD @MPishvaian @JohnEbbenMDPhD @stolaney1 @TNBCFoundation @LoiSher @BCJoyceO 4/19 #TumorBoardTuesday #BCSM @dr_yakupergun @fataranmd @BianchiniGP
π©π»βπ«Mini-Tweetorial 2
π Whatβs the SOC?
KN-522 protocol plus:
β¨CREATE-X: adj capecitabine if RD
β OS benefit vs no cape in 3.6y: 78.8 v 70.3%
π#NorikazuMasuda nejm.org
π©π»βπ«Mini-Tweetorial 2
π Whatβs the SOC?
KN-522 protocol plus:
β¨CREATE-X: adj capecitabine if RD
β OS benefit vs no cape in 3.6y: 78.8 v 70.3%
π#NorikazuMasuda nejm.org
@TumorBoardTues @maryam_lustberg @WLybaert @shimoi_oncology @AnisToumeh @MamMa_mimumemo @benjiwal @mariani_m97 @SheydaDoc @FelipeBatalini @Dr_RShatsky @DanielleZakon @Badr_AlBawardy @fedgiugliano @DraAnaCasas @LCalabreseDO @DVinsard @DrJeffreyGraham @Hanna_Huebner @hoperugo @FilippoMontemu1 @PGrivasMDPhD @MPishvaian @JohnEbbenMDPhD @stolaney1 @TNBCFoundation @LoiSher @BCJoyceO @dr_yakupergun @fataranmd @AmerGastroAssn @LehleSarah @DavidKrugMD @brunovalsi @volkmar_mueller @SoumarSchool @EdwardLoftus2 @markus_huebner @jenwhipkey @HeatherMoore16 @CarmenCriscit @SchairerIBDMD @abhenilmittal @EMittendorfMD @NAbuhadra @matteolambe @FilipaLynce @MaiaKayalMD @darioT_ @davidfaleckmd
@TumorBoardTues @maryam_lustberg @WLybaert @shimoi_oncology @AnisToumeh @MamMa_mimumemo @benjiwal @mariani_m97 @SheydaDoc @FelipeBatalini @Dr_RShatsky @DanielleZakon @Badr_AlBawardy @fedgiugliano @DraAnaCasas @LCalabreseDO @DVinsard @DrJeffreyGraham @Hanna_Huebner @hoperugo @FilippoMontemu1 @PGrivasMDPhD @MPishvaian @JohnEbbenMDPhD @stolaney1 @TNBCFoundation @LoiSher @BCJoyceO @dr_yakupergun @fataranmd @AmerGastroAssn @LehleSarah @DavidKrugMD @brunovalsi @volkmar_mueller @SoumarSchool @EdwardLoftus2 @markus_huebner @jenwhipkey @HeatherMoore16 @CarmenCriscit @SchairerIBDMD @abhenilmittal @EMittendorfMD @NAbuhadra @matteolambe @FilipaLynce @MaiaKayalMD @darioT_ @DavidFaleckMD 5/19 #TumorBoardTuesday #BreastCancer
π©π»βπ« Mini tweetorial 3 π©π»βπ«
πCan we minimize IO use?
π€In pCR cases on SOC, is IO needed in adj setting?
β¨GeparNuevo
πphase II (N=174)
πdurva + neoad chemo for TNBC w/o adju IO
ππ½OS of the pCR effect
π#SybilleLoibl annalsofoncology.org
π©π»βπ« Mini tweetorial 3 π©π»βπ«
πCan we minimize IO use?
π€In pCR cases on SOC, is IO needed in adj setting?
β¨GeparNuevo
πphase II (N=174)
πdurva + neoad chemo for TNBC w/o adju IO
ππ½OS of the pCR effect
π#SybilleLoibl annalsofoncology.org
@TumorBoardTues @maryam_lustberg @WLybaert @shimoi_oncology @AnisToumeh @MamMa_mimumemo @benjiwal @mariani_m97 @SheydaDoc @FelipeBatalini @Dr_RShatsky @DanielleZakon @Badr_AlBawardy @fedgiugliano @DraAnaCasas @LCalabreseDO @DVinsard @DrJeffreyGraham @Hanna_Huebner @hoperugo @FilippoMontemu1 @PGrivasMDPhD @MPishvaian @JohnEbbenMDPhD @stolaney1 @TNBCFoundation @LoiSher @BCJoyceO @dr_yakupergun @fataranmd @AmerGastroAssn @LehleSarah @DavidKrugMD @brunovalsi @volkmar_mueller @SoumarSchool @EdwardLoftus2 @markus_huebner @jenwhipkey @HeatherMoore16 @CarmenCriscit @SchairerIBDMD @abhenilmittal @EMittendorfMD @NAbuhadra @matteolambe @FilipaLynce @MaiaKayalMD @darioT_ 6/19 #TumorBoardTuesday
π©π»βπ«Mini tweetorial 4π©π»βπ«
πCan we minimize IO use?
βΌοΈNEEDβΌοΈlarger prospective dataβΌοΈ
Ongoing
β¨OptimICE-pCR: Pembro v observe TNBC had pCR after Chemo + Pembro
π@stolaney1 ncbi.nlm.nih.gov
π§Are you omitting IO post pCR off protocol?
π€Experiences?
π©π»βπ«Mini tweetorial 4π©π»βπ«
πCan we minimize IO use?
βΌοΈNEEDβΌοΈlarger prospective dataβΌοΈ
Ongoing
β¨OptimICE-pCR: Pembro v observe TNBC had pCR after Chemo + Pembro
π@stolaney1 ncbi.nlm.nih.gov
π§Are you omitting IO post pCR off protocol?
π€Experiences?
@TumorBoardTues @maryam_lustberg @WLybaert @shimoi_oncology @AnisToumeh @MamMa_mimumemo @benjiwal @mariani_m97 @SheydaDoc @FelipeBatalini @Dr_RShatsky @DanielleZakon @Badr_AlBawardy @fedgiugliano @DraAnaCasas @LCalabreseDO @DVinsard @DrJeffreyGraham @Hanna_Huebner @hoperugo @FilippoMontemu1 @PGrivasMDPhD @MPishvaian @JohnEbbenMDPhD @stolaney1 @TNBCFoundation @LoiSher @BCJoyceO @dr_yakupergun @fataranmd @AmerGastroAssn @LehleSarah @DavidKrugMD @brunovalsi @volkmar_mueller @SoumarSchool @EdwardLoftus2 @markus_huebner @jenwhipkey @HeatherMoore16 @CarmenCriscit @SchairerIBDMD @abhenilmittal @EMittendorfMD @NAbuhadra @matteolambe @FilipaLynce @MaiaKayalMD @darioT_ 7/19 #TumorBoardTuesday #BCSM
π©π»βπ«Mini-Tweetorial 5π©π»βπ«
πWere autoimmune disease patients studied?
β οΈKN-522 & most immunotherapy trials EXCLUDED pts with active autoimmune dz requiring recent (β2 years) immunosuppressionβ οΈ
πLack of data = subspecialty communication is key (MDT)
π©π»βπ«Mini-Tweetorial 5π©π»βπ«
πWere autoimmune disease patients studied?
β οΈKN-522 & most immunotherapy trials EXCLUDED pts with active autoimmune dz requiring recent (β2 years) immunosuppressionβ οΈ
πLack of data = subspecialty communication is key (MDT)
@TumorBoardTues @maryam_lustberg @WLybaert @shimoi_oncology @AnisToumeh @MamMa_mimumemo @benjiwal @mariani_m97 @SheydaDoc @FelipeBatalini @Dr_RShatsky @DanielleZakon @Badr_AlBawardy @fedgiugliano @DraAnaCasas @LCalabreseDO @DVinsard @DrJeffreyGraham @Hanna_Huebner @hoperugo @FilippoMontemu1 @PGrivasMDPhD @MPishvaian @JohnEbbenMDPhD @stolaney1 @TNBCFoundation @LoiSher @BCJoyceO @dr_yakupergun @fataranmd @AmerGastroAssn @LehleSarah @DavidKrugMD @brunovalsi @volkmar_mueller @SoumarSchool @EdwardLoftus2 @markus_huebner @jenwhipkey @HeatherMoore16 @CarmenCriscit @SchairerIBDMD @abhenilmittal 8/19 #TumorBoardTuesday #BCSM #IBD @curijoey @KoontzOncology @RashidLui @JenniferLitton @ibddoctor @IlanaSchlam @DrSGraff
π©π»βπ«Mini tweetorial 6 π©π»βπ«
π§What is approximate rate of autoimmune disease exacerbation seen in literature of patients with autoimmune diseases & use of IO?
π©π»βπ«Mini tweetorial 6 π©π»βπ«
π§What is approximate rate of autoimmune disease exacerbation seen in literature of patients with autoimmune diseases & use of IO?
@TumorBoardTues @maryam_lustberg @WLybaert @shimoi_oncology @AnisToumeh @MamMa_mimumemo @benjiwal @mariani_m97 @SheydaDoc @FelipeBatalini @Dr_RShatsky @DanielleZakon @Badr_AlBawardy @fedgiugliano @DraAnaCasas @LCalabreseDO @DVinsard @DrJeffreyGraham @Hanna_Huebner @hoperugo @FilippoMontemu1 @PGrivasMDPhD @MPishvaian @JohnEbbenMDPhD @stolaney1 @TNBCFoundation @LoiSher @BCJoyceO @dr_yakupergun @fataranmd @AmerGastroAssn @LehleSarah @DavidKrugMD @brunovalsi @volkmar_mueller @SoumarSchool @EdwardLoftus2 @markus_huebner @jenwhipkey @HeatherMoore16 @CarmenCriscit @SchairerIBDMD @abhenilmittal @curijoey @KoontzOncology @RashidLui @JenniferLitton @ibddoctor @IlanaSchlam @DrSGraff 9/19 #TumorBoardTuesday
π©π»βπ«Mini tweetorial 7π©π»βπ«
πWill I have an autoimmune dz flare on IO?
πReal-world data of tx outcomes of pts with autoimmune dz receiving IO
β‘οΈ β1/2 of pts had exacerbation regardless of dz activity/being on immunosuppression
πdoi.org
π©π»βπ«Mini tweetorial 7π©π»βπ«
πWill I have an autoimmune dz flare on IO?
πReal-world data of tx outcomes of pts with autoimmune dz receiving IO
β‘οΈ β1/2 of pts had exacerbation regardless of dz activity/being on immunosuppression
πdoi.org
@TumorBoardTues @maryam_lustberg @WLybaert @shimoi_oncology @AnisToumeh @MamMa_mimumemo @benjiwal @mariani_m97 @SheydaDoc @FelipeBatalini @Dr_RShatsky @DanielleZakon @Badr_AlBawardy @fedgiugliano @DraAnaCasas @LCalabreseDO @DVinsard @DrJeffreyGraham @Hanna_Huebner @hoperugo @FilippoMontemu1 @PGrivasMDPhD @MPishvaian @JohnEbbenMDPhD @stolaney1 @TNBCFoundation @LoiSher @BCJoyceO @dr_yakupergun @fataranmd @AmerGastroAssn @LehleSarah @DavidKrugMD @brunovalsi @volkmar_mueller @SoumarSchool @EdwardLoftus2 @markus_huebner @jenwhipkey @HeatherMoore16 @CarmenCriscit @SchairerIBDMD @abhenilmittal @curijoey @KoontzOncology @RashidLui @JenniferLitton @ibddoctor @IlanaSchlam 10/19 #TumorBoardTuesday #BCSM
π©π»βπ«Mini tweetorial 8π©π»βπ«
πWill I have an exacerbation of autoimmune dz on IO?
Useful papers:
πall AIs #MichelleCoureau frontiersin.org
πIBD @AntonioFaccior6 onlinelibrary.wiley.com
πIBD flare vs IO colitis sciencedirect.com
π©π»βπ«Mini tweetorial 8π©π»βπ«
πWill I have an exacerbation of autoimmune dz on IO?
Useful papers:
πall AIs #MichelleCoureau frontiersin.org
πIBD @AntonioFaccior6 onlinelibrary.wiley.com
πIBD flare vs IO colitis sciencedirect.com
frontiersin.org/articles/10.33β¦
Efficacy and Toxicity of Immune -Checkpoint Inhibitors in Patients With Preexisting Autoimmune Disorders
Immunotherapy is an important armamentarium for cancer treatment nowadays. Apart from their signific...
sciencedirect.com/science/articlβ¦
Immune Checkpoint Inhibitor Enterocolitis vs Idiopathic Inflammatory Bowel Disease
Immune checkpoint inhibitors have revolutionized management of advanced malignancies. However, their...
onlinelibrary.wiley.com/doi/abs/10.111β¦
Systematic review with metaβanalysis: safety and tolerability of immune checkpoint inhibitors in patients with preβexisting inflammatory bowel diseases
Alimentary Pharmacology & Therapeutics is a global pharmacology journal concerned with the effects o...
@TumorBoardTues @maryam_lustberg @WLybaert @shimoi_oncology @AnisToumeh @MamMa_mimumemo @benjiwal @mariani_m97 @SheydaDoc @FelipeBatalini @Dr_RShatsky @DanielleZakon @Badr_AlBawardy @fedgiugliano @DraAnaCasas @LCalabreseDO @DVinsard @DrJeffreyGraham @Hanna_Huebner @hoperugo @FilippoMontemu1 @PGrivasMDPhD @MPishvaian @JohnEbbenMDPhD @stolaney1 @TNBCFoundation @LoiSher @BCJoyceO @dr_yakupergun @fataranmd @AmerGastroAssn @LehleSarah @DavidKrugMD @brunovalsi @volkmar_mueller @SoumarSchool @EdwardLoftus2 @markus_huebner @jenwhipkey @HeatherMoore16 @CarmenCriscit @SchairerIBDMD @abhenilmittal @curijoey @KoontzOncology @RashidLui @JenniferLitton @ibddoctor @IlanaSchlam @AntonioFaccior6 11/19 #TumorBoardTuesday
π©π»βπ«Mini tweetorial 9
πWill IO be effective while on immunosuppression?
In humans: IS use has either NONE or POSSIBLY detrimental effect on IO efficacy
β‘οΈUse as MUCH as NEEDED & as LITTLE as POSSIBLEβ‘οΈ
πnature.com
πacademic.oup.com
π©π»βπ«Mini tweetorial 9
πWill IO be effective while on immunosuppression?
In humans: IS use has either NONE or POSSIBLY detrimental effect on IO efficacy
β‘οΈUse as MUCH as NEEDED & as LITTLE as POSSIBLEβ‘οΈ
πnature.com
πacademic.oup.com
nature.com/articles/s4169β¦
Immunosuppression for immune-related adverse events during checkpoint inhibition: an intricate balance
npj Precision Oncology - Immunosuppression for immune-related adverse events during checkpoint inhib...
academic.oup.com/ecco-jcc/articβ¦
P729 The SAPPHIRE registry: Safety of immunosuppression in a prospective cohort of inflammatory bowel disease patients with a HIstoRy of CancEr
AbstractBackground. Previous retrospective studies have demonstrated that patients with inflammatory...
@TumorBoardTues @maryam_lustberg @WLybaert @shimoi_oncology @AnisToumeh @MamMa_mimumemo @benjiwal @mariani_m97 @SheydaDoc @FelipeBatalini @Dr_RShatsky @DanielleZakon @Badr_AlBawardy @fedgiugliano @DraAnaCasas @LCalabreseDO @DVinsard @DrJeffreyGraham @Hanna_Huebner @hoperugo @FilippoMontemu1 @PGrivasMDPhD @MPishvaian @JohnEbbenMDPhD @stolaney1 @TNBCFoundation @LoiSher @BCJoyceO @dr_yakupergun @fataranmd @AmerGastroAssn @LehleSarah @DavidKrugMD @brunovalsi @volkmar_mueller @SoumarSchool @EdwardLoftus2 @markus_huebner @jenwhipkey @HeatherMoore16 @CarmenCriscit @SchairerIBDMD @abhenilmittal @curijoey @KoontzOncology @RashidLui @JenniferLitton @ibddoctor 12/19 #TumorBoardTuesday
π©π»βπ«Mini tweetorial 10π©π»βπ«
πHow to decide next steps?
βοΈCONSULT disease subspecialist early & often as part of txβΌοΈ
πDepending on autoimmune dz & status:
ππ»ββοΈSafe or not for IO?
π·π»ββοΈSafer IS?
π π»ββοΈStop IS?
@PGrivasMDPhD @PTarantinoMD jnccn.org
π©π»βπ«Mini tweetorial 10π©π»βπ«
πHow to decide next steps?
βοΈCONSULT disease subspecialist early & often as part of txβΌοΈ
πDepending on autoimmune dz & status:
ππ»ββοΈSafe or not for IO?
π·π»ββοΈSafer IS?
π π»ββοΈStop IS?
@PGrivasMDPhD @PTarantinoMD jnccn.org
@TumorBoardTues @maryam_lustberg @WLybaert @shimoi_oncology @AnisToumeh @MamMa_mimumemo @benjiwal @mariani_m97 @SheydaDoc @FelipeBatalini @Dr_RShatsky @DanielleZakon @Badr_AlBawardy @fedgiugliano @DraAnaCasas @LCalabreseDO @DVinsard @DrJeffreyGraham @Hanna_Huebner @hoperugo @FilippoMontemu1 @PGrivasMDPhD @MPishvaian @JohnEbbenMDPhD @stolaney1 @TNBCFoundation @LoiSher @BCJoyceO @dr_yakupergun @fataranmd @AmerGastroAssn @LehleSarah @DavidKrugMD @brunovalsi @volkmar_mueller @SoumarSchool @EdwardLoftus2 @markus_huebner @jenwhipkey @HeatherMoore16 @CarmenCriscit @SchairerIBDMD @abhenilmittal @curijoey @KoontzOncology @RashidLui @JenniferLitton @ibddoctor 13/19 #TumorBoardTuesday #BCSM #Crohns @NickPowellLab @ANaingMD
π©π»βπ«Mini tweetorial 11π©π»βπ«
πHow to decide next steps?
πOngoing trial with upcoming data
Vedolizumab/VDZ: more gut-selective
π€VDZ allow for more IO efficacy?
π€·ββοΈ We will see!
πrecruiting: clinicaltrials.gov
π©π»βπ«Mini tweetorial 11π©π»βπ«
πHow to decide next steps?
πOngoing trial with upcoming data
Vedolizumab/VDZ: more gut-selective
π€VDZ allow for more IO efficacy?
π€·ββοΈ We will see!
πrecruiting: clinicaltrials.gov
@TumorBoardTues @maryam_lustberg @WLybaert @shimoi_oncology @AnisToumeh @MamMa_mimumemo @benjiwal @mariani_m97 @SheydaDoc @FelipeBatalini @Dr_RShatsky @DanielleZakon @Badr_AlBawardy @fedgiugliano @DraAnaCasas @LCalabreseDO @DVinsard @DrJeffreyGraham @Hanna_Huebner @hoperugo @FilippoMontemu1 @PGrivasMDPhD @MPishvaian @JohnEbbenMDPhD @stolaney1 @TNBCFoundation @LoiSher @BCJoyceO @dr_yakupergun @fataranmd @AmerGastroAssn @LehleSarah @DavidKrugMD @brunovalsi @volkmar_mueller @SoumarSchool @EdwardLoftus2 @markus_huebner @jenwhipkey @HeatherMoore16 @CarmenCriscit @SchairerIBDMD @abhenilmittal @curijoey @KoontzOncology 14/19 #TumorBoardTuesday #BCSM #Crohns @JeanFredericCo1 @Dana_Lukin @charlie_lees @LauraRaffalsMD @martacalvo12
π©π»βπ«Mini tweetorial 12π©π»βπ«
πHow to decide next steps?
Check these reviews for further information on alternatives to IFX
π#HangShim onlinelibrary.wiley.com
π©π»βπ«Mini tweetorial 12π©π»βπ«
πHow to decide next steps?
Check these reviews for further information on alternatives to IFX
π#HangShim onlinelibrary.wiley.com
@TumorBoardTues @maryam_lustberg @WLybaert @shimoi_oncology @AnisToumeh @MamMa_mimumemo @benjiwal @mariani_m97 @SheydaDoc @FelipeBatalini @Dr_RShatsky @DanielleZakon @Badr_AlBawardy @fedgiugliano @DraAnaCasas @LCalabreseDO @DVinsard @DrJeffreyGraham @Hanna_Huebner @hoperugo @FilippoMontemu1 @PGrivasMDPhD @MPishvaian @JohnEbbenMDPhD @stolaney1 @TNBCFoundation @LoiSher @BCJoyceO @dr_yakupergun @fataranmd @AmerGastroAssn @LehleSarah @DavidKrugMD @brunovalsi @volkmar_mueller @SoumarSchool @EdwardLoftus2 @markus_huebner @jenwhipkey @HeatherMoore16 @CarmenCriscit @SchairerIBDMD @abhenilmittal @curijoey @KoontzOncology @JeanFredericCo1 @Dana_Lukin @charlie_lees @LauraRaffalsMD @MartaCalvo12 15/19 #TumorBoardTuesday
π©π»βπ«Mini tweetorial 13π©π»βπ«
πHow to decide next steps?
πUpcoming helpful data from ongoing trials
Pembro + Infliximab (IFX) in melanoma
π#RyanSullivan recruiting clinicaltrials.gov
π€Is it safe & efficacious to use IO + IS at start?
π€·ββοΈWe will see!
π©π»βπ«Mini tweetorial 13π©π»βπ«
πHow to decide next steps?
πUpcoming helpful data from ongoing trials
Pembro + Infliximab (IFX) in melanoma
π#RyanSullivan recruiting clinicaltrials.gov
π€Is it safe & efficacious to use IO + IS at start?
π€·ββοΈWe will see!
@TumorBoardTues @maryam_lustberg @WLybaert @shimoi_oncology @AnisToumeh @MamMa_mimumemo @benjiwal @mariani_m97 @SheydaDoc @FelipeBatalini @Dr_RShatsky @DanielleZakon @Badr_AlBawardy @fedgiugliano @DraAnaCasas @LCalabreseDO @DVinsard @DrJeffreyGraham @Hanna_Huebner @hoperugo @FilippoMontemu1 @PGrivasMDPhD @MPishvaian @JohnEbbenMDPhD @stolaney1 @TNBCFoundation @LoiSher @BCJoyceO @dr_yakupergun @fataranmd @AmerGastroAssn @LehleSarah @DavidKrugMD @brunovalsi @volkmar_mueller @SoumarSchool @EdwardLoftus2 @markus_huebner @jenwhipkey @HeatherMoore16 @CarmenCriscit @SchairerIBDMD @abhenilmittal @curijoey @KoontzOncology @JeanFredericCo1 @Dana_Lukin @charlie_lees 16/19 #TumorBoardTuesday #IBD #BreastCancer
π©π»βπ«Mini tweetorial 14π©π»βπ«
πHow do we decide next steps?
πMany current & upcoming treatments for #Crohnβs:
π§How they will impact IO use will need to be addressedβΌοΈ
π@Badr_AlBawardy @RShivashankarMD
frontiersin.org
π©π»βπ«Mini tweetorial 14π©π»βπ«
πHow do we decide next steps?
πMany current & upcoming treatments for #Crohnβs:
π§How they will impact IO use will need to be addressedβΌοΈ
π@Badr_AlBawardy @RShivashankarMD
frontiersin.org
@TumorBoardTues @maryam_lustberg @WLybaert @shimoi_oncology @AnisToumeh @MamMa_mimumemo @benjiwal @mariani_m97 @SheydaDoc @FelipeBatalini @Dr_RShatsky @DanielleZakon @Badr_AlBawardy @fedgiugliano @DraAnaCasas @LCalabreseDO @DVinsard @DrJeffreyGraham @Hanna_Huebner @hoperugo @FilippoMontemu1 @PGrivasMDPhD @MPishvaian @JohnEbbenMDPhD @stolaney1 @TNBCFoundation @LoiSher @BCJoyceO @dr_yakupergun @fataranmd @AmerGastroAssn @LehleSarah @DavidKrugMD @brunovalsi @volkmar_mueller @SoumarSchool @EdwardLoftus2 @markus_huebner @jenwhipkey @HeatherMoore16 @CarmenCriscit @SchairerIBDMD @abhenilmittal @curijoey @KoontzOncology @JeanFredericCo1 @Dana_Lukin @charlie_lees @RShivashankarMD 17/19 #TumorBoardTuesday #BCSM #IBD
π©π»βπ«Mini tweetorial 15π©π»βπ«
π§After reviewing all the data, should immunotherapy trials allow for inclusion of patients with autoimmune disease actively treated with immunosuppression?
π€Share your impressions!!!
π©π»βπ«Mini tweetorial 15π©π»βπ«
π§After reviewing all the data, should immunotherapy trials allow for inclusion of patients with autoimmune disease actively treated with immunosuppression?
π€Share your impressions!!!
@TumorBoardTues @maryam_lustberg @WLybaert @shimoi_oncology @AnisToumeh @MamMa_mimumemo @benjiwal @mariani_m97 @SheydaDoc @FelipeBatalini @Dr_RShatsky @DanielleZakon @Badr_AlBawardy @fedgiugliano @DraAnaCasas @LCalabreseDO @DVinsard @DrJeffreyGraham @Hanna_Huebner @hoperugo @FilippoMontemu1 @PGrivasMDPhD @MPishvaian @JohnEbbenMDPhD @stolaney1 @TNBCFoundation @LoiSher @BCJoyceO @dr_yakupergun @fataranmd @AmerGastroAssn @LehleSarah @DavidKrugMD @brunovalsi @volkmar_mueller @SoumarSchool @EdwardLoftus2 @markus_huebner @jenwhipkey @HeatherMoore16 @CarmenCriscit @SchairerIBDMD @abhenilmittal @curijoey @KoontzOncology @JeanFredericCo1 @Dana_Lukin @charlie_lees @RShivashankarMD 18/19 #TumorBoardTuesday
Back to our caseπ
π©π»β𦱠Infliximab/AZA therapy changed to vedolizumab in response to #BreastCancer diagnosis
Back to our caseπ
π©π»β𦱠Infliximab/AZA therapy changed to vedolizumab in response to #BreastCancer diagnosis
@TumorBoardTues @maryam_lustberg @WLybaert @shimoi_oncology @AnisToumeh @MamMa_mimumemo @benjiwal @mariani_m97 @SheydaDoc @FelipeBatalini @Dr_RShatsky @DanielleZakon @Badr_AlBawardy @fedgiugliano @DraAnaCasas @LCalabreseDO @DVinsard @DrJeffreyGraham @Hanna_Huebner @hoperugo @FilippoMontemu1 @PGrivasMDPhD @MPishvaian @JohnEbbenMDPhD @stolaney1 @TNBCFoundation @LoiSher @BCJoyceO @dr_yakupergun @fataranmd @AmerGastroAssn @LehleSarah @DavidKrugMD @brunovalsi @volkmar_mueller @SoumarSchool @EdwardLoftus2 @markus_huebner @jenwhipkey @HeatherMoore16 @CarmenCriscit @SchairerIBDMD @abhenilmittal @curijoey @KoontzOncology @JeanFredericCo1 @Dana_Lukin @charlie_lees @RShivashankarMD 19/19 #TumorBoardTuesday
π©π»β Received neoadjuvant ddAC/pembro β‘οΈ CbT/pembro as per KEYNOTE-522
π No GI toxicity
ποΈ After 6 months
βοΈUnderwent surgery and achieved pCR
πContinues on adjuvant pembro
πNo further toxicity or IBD flare
ποΈClosely followed up by Med Onc and GI
π©π»β Received neoadjuvant ddAC/pembro β‘οΈ CbT/pembro as per KEYNOTE-522
π No GI toxicity
ποΈ After 6 months
βοΈUnderwent surgery and achieved pCR
πContinues on adjuvant pembro
πNo further toxicity or IBD flare
ποΈClosely followed up by Med Onc and GI
@TumorBoardTues @maryam_lustberg @WLybaert @shimoi_oncology @AnisToumeh @MamMa_mimumemo @benjiwal @mariani_m97 @SheydaDoc @FelipeBatalini @Dr_RShatsky @DanielleZakon @Badr_AlBawardy @fedgiugliano @DraAnaCasas @LCalabreseDO @DVinsard @DrJeffreyGraham @Hanna_Huebner @hoperugo @FilippoMontemu1 @PGrivasMDPhD @MPishvaian @JohnEbbenMDPhD @stolaney1 @TNBCFoundation @LoiSher @BCJoyceO @dr_yakupergun @fataranmd @AmerGastroAssn @LehleSarah @DavidKrugMD @brunovalsi @volkmar_mueller @SoumarSchool @EdwardLoftus2 @markus_huebner @jenwhipkey @HeatherMoore16 @CarmenCriscit @SchairerIBDMD @abhenilmittal @curijoey @KoontzOncology @JeanFredericCo1 @Dana_Lukin @charlie_lees #PostTest Q1οΈβ£ #TumorBoardTuesday
ππ½#CME evalπ integrityce.com
ππ½ALL CME π integrityce.com
π€@maryam_lustberg @adrianakahnmd taught us early stage TNBC + autoimmune dz, test your π§
π§What neoadj tx?
36yoπ©πΌ
T2N1 TNBC
wild-type germ BRCA
#Crohns: IFX/AZA
ππ½#CME evalπ integrityce.com
ππ½ALL CME π integrityce.com
π€@maryam_lustberg @adrianakahnmd taught us early stage TNBC + autoimmune dz, test your π§
π§What neoadj tx?
36yoπ©πΌ
T2N1 TNBC
wild-type germ BRCA
#Crohns: IFX/AZA
integrityce.com/TBT2023
Tumor Board Tuesday 2023 Conversations
Tumor Board Tuesdays is a regularly scheduled, Twitter-based case discussion forum led by expert fac...
integrityce.com/TBTeval23
Tumor Board Tuesday Evaluation 2023 (ID: i854/i855/i862/i865)
Take this survey powered by surveymonkey.com. Create your own surveys for free.
@TumorBoardTues @maryam_lustberg @WLybaert @shimoi_oncology @AnisToumeh @MamMa_mimumemo @benjiwal @mariani_m97 @SheydaDoc @FelipeBatalini @Dr_RShatsky @DanielleZakon @Badr_AlBawardy @fedgiugliano @DraAnaCasas @LCalabreseDO @DVinsard @DrJeffreyGraham @Hanna_Huebner @hoperugo @FilippoMontemu1 @PGrivasMDPhD @MPishvaian @JohnEbbenMDPhD @stolaney1 @TNBCFoundation @LoiSher @BCJoyceO @dr_yakupergun @fataranmd @AmerGastroAssn @LehleSarah @DavidKrugMD @brunovalsi @volkmar_mueller @SoumarSchool @EdwardLoftus2 @markus_huebner @jenwhipkey @HeatherMoore16 @CarmenCriscit @SchairerIBDMD @abhenilmittal @curijoey @KoontzOncology @JeanFredericCo1 @Dana_Lukin @charlie_lees #PostTest Q2οΈβ£ #BCSM #TumorBoardTuesday
ππ½Free CME π integrityce.com
π§Which of these studies has shown that efficacy of neoadjuvant IO, without addβl adjuvant IO, is independent of achieving pCR to neoadjuvant chemotherapy plus IO for patients with TNBC?
ππ½Free CME π integrityce.com
π§Which of these studies has shown that efficacy of neoadjuvant IO, without addβl adjuvant IO, is independent of achieving pCR to neoadjuvant chemotherapy plus IO for patients with TNBC?
Loading suggestions...